Sentence: Patients aged 15 to 60 years , presenting with newly diagnosed acute myeloid leukemia ( AML ) were randomized to receive either high-dose cytarabine , 3 g/m2 12 hourly on days 1 , 3 , 5 , and 7 for 8 doses , daunorubicin 50 mg/m2 days 1 to 3 , etoposide 75 mg/m2 days 1 to 7 , ( HIDAC-3 - 7 ) or standard dose cytarabine 100 mg/m2 continuous intravenous infusion for 7 days with daunorubicin and etoposide at the same dose and schedule as above ( 7 - 3 - 7 ) .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['cytarabine', 'daunorubicin', 'etoposide'], 'is_context_needed': True}, {'class': 'COMB', 'spans': [3, 4, 5], 'is_context_needed': True}]